

## Curriculum Vitae

Name: ITARU ENDO MD, PhD

Nationality: Japan

Office Address:

Department of Gastroenterological Surgery, Yokohama City University,  
Graduate school of Medicine.

3-9 Fukuura, Kanazawaku, Yokohama, Japan, 2360004,

Education:

Yokohama City University School of Medicine, 1, April, 1979 - 31,  
March, 1985, Doctor of Medicine, Yokohama, Japan

Work experience:

1985 Licensed Physician & Board Certification

1987 Fujisawa Municipal Hospital, Department of Surgery,

1988 Instructor, Teikyo University Mizonokuchi Hospital, Surgery

1994 Clinical investigator, UCLA Dumont Liver Transplantation  
Center

2002 Assistant Prof, Gastroenterological Surgery, Yokohama City  
Univ.

2006 Research Fellow, Memorial Sloan-Kettering Cancer Center, New  
York, USA,

2009 Professor and Chairman, Gastroenterological Surgery,  
Yokohama City Univ.

2016 Deputy Director, Yokohama City University Hospital.

2018 Executive Director/Vice President, Yokohama City University

Executive Board Member:

Japanese Society of Hepato-Biliary-Pancreatic Surgery

Japanese Society of Gastroenterological Surgery

Japan Biliary Association

Councilor:

Japan Surgical Society

Japanese Society of Gastroenterological Surgery

Japan Society of Clinical Oncology

Japan Surgical Association

International Societies

IHPBA

SSAT

ISS/SIC

IASGO

### Editorial Board

Annals of Surgical Oncology (Hepatobiliary section)  
Annals of Gastroenterological Surgery (Associate Editor)  
Journal of HepatoBiliary Pancreatic Sciences (Co-editor)  
Journal of Gastrointestinal Surgery  
International Journal of Clinical Oncology  
Japanese Journal of Gastroenterological Surgery (Editor in Chief)  
JMA Journal

### Specialty and Present Interest:

HBP surgery, Image-guided surgery, Immunomodulation, Septic DIC & organ failure, Education for young surgeons.

### Biosketch

Dr Endo is a Japanese Surgeon currently the Professor and Chairman of Yokohama City University Graduate School of Medicine. He graduated Yokohama City University in 1985 and then completed his residency in the Second Department of Surgery, Yokohama City University Hospital. He spent 28 years at Yokohama City University.

In 1994, he has studied liver transplantation as a clinical investigator in UCLA liver transplantation center (Prof Busutil). In 2006, he visited Memorial Sloan Kettering Cancer Center as a clinical fellow (Prof Jarnagin & Prof Blumgart). In 2009, he was appointed as Professor and Chairman of Department of Gastroenterological Surgery.

Currently, his main fields of interest are simulation and navigation using 3D imaging in complex hepatobiliary cancers such as perihilar cholangiocarcinoma. Also his research has examined the immunological impact of neoadjuvant chemoradiotherapy in pancreatic cancer.

He is the author of more than 400 publications in the peer reviewed journals. He also dedicates his effort to the editorial works in several international and domestic journals. He got the Publons Peer Review Awards 2018 (For placing in the top 1% reviewers in 'Clinical Medicine').

### 5 most recent publications

#1 Endo I, Kumamoto T, Matsuyama R.

Postoperative complications and mortality: Are they unavoidable?

Ann Gastroenterol Surg 2017;1:160-163. 13 October 2017

<https://doi.org/10.1002/ags3.12045>

#2 Endo I, Takada T, Hwang TL, Akazawa K, Mori R, Miura F, Yokoe M, Itoi T, Gomi H, Chen MF, Jan YY, Ker CG, Wang HP, Kiriya S, Wada K, Yamaue H, Miyazaki M, Yamamoto M. Optimal treatment strategy for acute cholecystitis

based on predictive factors: Japan-Taiwan multicenter cohort study. *J Hepatobiliary Pancreat Sci.* 2017 Jun;24(6):346-361. doi: 10.1002/jhbp.456. Epub 2017 May 31

#3 Miyake K, Mori R, Mori R, Homma Y, Matsuyama R, Okayama A, Murakami T, Hirano H, Endo I: MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. *Journal of Surgical Research*,220:391-401,2017.

#4 Yabushita Y, Mori R, Taniguchi K, Matsuyama R, Kumamoto T, Sakamaki K, Kubota K, Endo I: Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer. *Anticancer Res*,37(5):2465-2476,2017.

#5 Murakami T, Homma Y, Matsuyama R, Mori R, Miyake K, Tanaka Y, Den K, Nagashima Y, Nakazawa M, Hiroshima Y, Ueda M, Tanaka K, Hoffman RM, Bouvet M, Endo I: Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression. *J Surg Oncol*, 116(3) :416-426,2017.